Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies

Cancer Journal

Volumn 16, Issue 2, 2010, Pages 163-175

  Kennedy, Andrew S ^a,b   Salem, Riad ^c  

^a Wake Radiology Oncology   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Brachytherapy; Breast; Colorectal; Hepatocellular; Liver; Neuroendocrine; SIRT; Yttrium 90

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MICROSPHERE; OXALIPLATIN; YTTRIUM 90;

ACUTE TOXICITY; AORTOGRAPHY; ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL TRIAL; COLORECTAL CANCER; FATIGUE; FEVER; GASTROINTESTINAL TRACT; HUMAN; LIVER ABSCESS; LIVER CANCER; LUNG SHUNTING; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PAIN; PANCREATITIS; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION SAFETY; RADIOEMBOLIZATION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT CONTRAINDICATION; ULCER; VOMITING; WEIGHT REDUCTION;

BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MICROSPHERES; NEUROENDOCRINE TUMORS; YTTRIUM RADIOISOTOPES;

EID: 77951478799     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181d7e8cf     Document Type: Review

References (136)

1. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278. (Pubitemid 44259009)
2. Ariel IM. Radioactive isotopes for adjuvant cancer therapy. Arch Surg. 1964;89:244-249.
3. Flynn WJ. [The treatment of pulmonary metastases with microspheres of yttrium 90]. Minerva Med. 1967;58:4498-4500
4. Greene WM. Embolization of dog prostates with yttrium-90 microspheres. J Urol. 1963;90:451-457.
5. Blanchard RJ, LaFave JW, Kim YS. Treatment of patients with advanced cancer using Y-90 microspheres. Cancer. 1965;18:375-380.
6. Mantravadi RV, Spigos DG, Tan WS, et al. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology. 1982;142:783-786.
7. Wollner I, Knutsen C, Smith P, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer. 1988;61:1336-1344.
8. Wollner IS, Knutsen CA, Ullrich KA, et al. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res. 1987;47:3285-3290.
9. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere® ) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572-586.
10. Kulik LM, Mulcahy MF, Hunter RD, et al. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl. 2005;11:1127-1231.
11. Rhee TK, Omary RA, Gates V, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2005;16:1085-1091.
12. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
13. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up [see comments]. J Nucl Med. 1994;35:1637-1644.
14. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:800-804. (Pubitemid 47418394)
15. Coldwell D, Kennedy AS, Van Echo DA, et al. Feasibility of treatment of hepatic tumors utilizing embolization with yttrium-90 glass microspheres. J Vasc Interv Radiol. 2001;12(S1):S113.
16. Herba M, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol. 2002;29:152-159. (Pubitemid 34297286)
17. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology. 1988;169:311-314.
18. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
19. Kennedy AS, Coldwell D, Nutting C, et al. 90Y-microspheres in the treatment of colorectal metastases: USA experience. In: Khayat D, Hortobagyi GN, eds. Fifteenth International Congress on Anti-Cancer Treatment. Paris, France: T.C.O.; 2004:285.
20. Kennedy AS, Salem R. Comparison of two 90Yttrium microsphere agents for hepatic artery brachytherapy. Proceedings of the 14th International Congress on Anti-Cancer Treatment, 2003;1: 156.
21. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
22. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-592. (Pubitemid 350092259)
23. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005;16:911-935. (Pubitemid 40993515)
24. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
25. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
26. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase II trial of SIR-spheres plus flrorouracil/leucovrin chemotherapy versus fluororacil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78-85.
27. Sharma RA, van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106.
28. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
29. van Hazel G, Turner D, Gebski V. Impact of 90Y resin microspheres on health-related quality of life (HRQoL) in patients with colorectal cancer (CRC) liver metastases receiving first-line chemotherapy. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; Orlando, FL; 2009. Abs 419.
30. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fluorouracilrefractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27:4089-4095.
31. Cosimelli M, Mancini R, Carpanese L, et al. Clinical safety and efficacy of 90Yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial. ASCO Annual Meeting Proceedings. J Clin Oncol. 2008;26(May 20 Suppl): Abs. 4078.
32. Van den Eynde M, Hendlisz A, Peeters M, et al. Prospective randomized study comparing intra-arterial injection of yttrium-90 resin microspheres with protracted IV 5FU continuous infusion versus IV 5FU continuous infusion alone for patients with liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Poster presentation at the American Association of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2009;27(Suppl 7s):Abs. 4096.
33. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009; 115:1849-1858.
34. Ricke J, Rühl R, Seidensticker M, et al. Extensive liver-dominant colorectal (CRC) metastases failing multiple lines of systemic chemotherapy treated by 90Y Radioembolisation: a matched-pair analysis. Poster presentation, 11th World Congress of Gastrointestinal Cancer. Ann Oncol. 2009;20(Suppl 6:vi24):Abs. PD-002.
35. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187-1195.
36. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311-1319.
37. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.
38. Hoffmann RT, Jakobsa TF, Kubisch CH, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-is it feasible? Eur J Radiol. In press.
39. Van den Eynde M, Flamen P, El Nakadi I, et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med. 2008;33:697-699.
40. Young JY, Rhee T, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382.
41. Sato, K, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (therasphere® ): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;522-529.
42. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81.
43. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742.
44. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol. 2007; 188:768-775.
45. Ibrahim SM, Lewandowski RJ, Sato KT, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14:1664-1669.
46. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587-1596.
47. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335-345.
48. Iñarrairaegui M, Thurston KG, Martinez-Cuesta A. Radioembolization of hepatocellular carcinoma in patients presenting with portal vein occlusion: a safety analysis. Second International Liver Cancer Association meeting; 2008:Abs. 140.
49. Sangro B, et al. Nodularity is a strong predictor of survival following treatment with radioembolisation using 90Y-labelled resin microspheres in unresectable hepatocellular carcinoma: preliminary results from a European multi-centre evaluation. Presented at the 3rd International Liver Cancer Association 2009 Annual Conference; 4-6 September, 2009; Milan, Italy, Abs. 129.
50. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
51. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2009;138:52-64.
52. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
53. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008; 113:921-929.
54. Meranze SG, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Soc Interv Radiol. 2007: Abs. 422.
55. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multiinstitutional experience. Ann Surg. 2008;247:1029-1035.
56. Bangash AK, Atassi B, Kaklamani V, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621-628.
57. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19: 683-690.
58. Moroz P, Anderson JE, Van Hazel G, et al. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol. 2001;78:248-252.
59. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992; 62:105-110.
60. Goin JE, Dancey JE, Roberts C, et al. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med. 2004;3:49-56.
61. Stubbs R, Cannan R, Mitchell A, et al. An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases. GI Cancer. 1999;3:135-143.
62. Gray B, van Hazel G, Buck M, et al. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer. 2000;3:249-257.
63. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90Yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5:294-302.
64. Stubbs R, Wickremesekera S. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford). 2004;6:133-139.
65. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004; 45:1892-1897.
66. Pennington KL, Gulec SA, Bruetman D, et al. Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases. ASCO Annual Meeting Proceedings. J Clin Oncol. 2008; 26(May 20 Suppl):Abs. 15011.
67. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937-945.
68. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg. 2006;76:696-703.
69. Boppudi S, Wickremesekera SK, Nowitz M, et al. Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. Australas Radiol. 2006;50:570-577.
70. Murthy R, Eng C, Krishnan S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18:1588-1591.
71. Tan TH, Kosmider S, Yip D, et al. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol. 2008;26(May 20 Suppl):Abs. 15080.
72. Kennedy AS, Kreuk P, Jakobs T, et al. Effects of anti-angiogenic therapy and chemotherapy on 90Y-microsphere treatment of colorectal liver metastases. Poster presentation at the 20th International Congress on Anti Cancer Treatment (ICACT). 2009:Abs. IC/AB159.
73. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009;32:1179-1186.
74. Campbell JM, Wong CO, Muzik O, et al. Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. Int J Radiat Oncol Biol Phys. 2009;74:313-320.
75. Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70:2250-2254.
76. Lau WY, Ho S, Leung WT, et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology. 2001;48:338-340.
77. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994-999.
78. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 suppl 1): S107-S110.
79. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90Yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592.
80. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S194-S205.
81. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres [In Process Citation]. J Nucl Med. 2000;41:1673-1681.
82. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology. 2004;13:73-79.
83. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16(2 Pt 1):205-213. (Pubitemid 40322293)
84. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195-203. (Pubitemid 40322292)
85. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800.
86. El Fouly A, Ertle J, Antoch G, et al. Response rate according to WHO, RECIST and EASL criteria after radioembolization of yttrium-90 glass microspheres in advanced hepatocellular carcinoma: a European pilot phase II study. 44th Annual Meeting of the European Association for the Study of the Liver (EASL). J Hepatol, 2009;20(Suppl 1):S22 Abs. 51.
87. D'Avola D, Iñarrairaegui M, Bilbao JI, et al. Extended survival in patients with unresectable advanced hepatocellular carcinoma treated using radioembolization. 2nd International Liver Cancer Association meeting; 2008: Abs. P-139.
88. Woodall CE, Scoggins CR, Ellis SF, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg. 2009;208:375-382.
89. Minocha J, Kulik L, Ibrahim SM, et al. Prognostic value of lung shunting fraction in patients undergoing Yttrium-90 radioembolization for HCC. 2nd International Liver Cancer Association meeting. September 2008:Abs. P-115.
90. Romito R, Mazzaferro V, Spreafico C, et al. Intra-hepatic arterial radioembolization with 90Y-glass microspheres for hepatocellular carcinoma with macrovascular invasion: preliminary results. 2nd International Liver Cancer Association meeting. September 2008: Abs. P-142.
91. Carpanese L, Pizzi G, Vallati GE, et al. Role of the hepatic intra-arterial injection of Yttrium-90 microspheres in unresectable hepatocellular carcinoma: preliminary experience and clinical results. Cardiovascular and Interventional Radiology of Europe (CIRSE) meeting; 2008: Abs. 3009.2.
92. Iñarrairaegui M, D'Avola D, Rodriguez M, et al. Prognostic factors among patients with hepatocellular carcinoma (HCC) treated by Y90-radioembolization (Y90-RE). 44th Annual Meeting of the European Association for the Study of the Liver (EASL). J Hepatol. 2009; 20(Suppl 1): S291, Abs. 795.
93. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liverdominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20:360-367.
94. Reardon KA, McIntosh AF, Shilling AT, et al. Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities. Technol Cancer Res Treat. 2009;8:71-77.
95. Riaz A, Lewandowski RJ, Ryu RK, et al. Chemoembolization vs TACE: comparison of toxicity, imaging response and long-term outcomes in 100 TACE vs 104 Y90 patients. Abstract presentation at Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26(2S):Abs 215.
96. Scanlon T, Riaz A, Lewandowski RJ, et al. Treatment of solitary HCC: comparison of TACE and Y90 radioembolization. Abstract presentation at Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26(2S): Abs 195.
97. Khanna V, Dhanasekaran R, Kooby DA, et al. Comparison of survival benefits of conventional TACE, Precision TACE (drug eluting beads with doxorubicin) and Yttrium-90 radioembolization (SIR-Spheres) for unresect-able HCC. Presented at the Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26(2S):S84;Abs 217.
98. Moreno Luna LE, Sanchez W, James AC, et al. Survival of patients treated with Yttrium-90 radioembolisation vs chemoembolisation for unresectable hepatocellular carcinoma. Absract presented at the 3rd International Liver Cancer Association (ILCA) meeting; 2009: Abs. O-033.
99. Iñarrairaegui M, Thurston KG, Rodriguez M, et al. 90Y radioembolization using resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. Poster presentation at the American Association for the Study of the Liver; 2009: Abs. 1730.
100. Sangro B, Cianni R, Ezziddin S, et al. Predictors of survival following radioembolization using 90Y-labeled resin microspheres in unresectable hepatocellular carcinoma (HCC): results from a European multi-center evaluation. Poster presentation at the American Association for the Study of the Liver; 2009: Abs. 1712.
101. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119-2128.
102. Coldwell D. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres. Ann Oncol. 2006;17(Suppl 6): vi56, Abs P-102.
103. Saxena A, Bester L, Chua TC, et al. Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: a Preliminary Assessment of This Novel Treatment Option. Ann Surg Oncol. 2010;17:484-491.
104. Khanna V, Dhanasekaran R, Barron BJ, et al. Yttrium-90 radioembolization (SIR-Spheres) for cholangiocarcinoma: preliminary study. Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26(2S):S116-S117, Abs. 309.
105. Kennedy AS, Dezarn W, McNeillie P, et al. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after 90 Y-microsphere brachytherapy. Brachytherapy. 2006;5:103-104.
106. McGrath S, Kennedy A, Dezarn W. Resin 90Y-microsphere radioembolisation is effective in controlling hepatic metastases from neuroendocrine primary cancers. Emerging trends in radioembolization using microspheres: 3rd Annual Clinical Symposium; Scottsdale, AZ; May 4-5, 2007.
107. Kalinowski M, Dressler M, König A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137-142.
108. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145-151.
109. Granberg D, Garske U, Welin S, et al. Selective internal radiation therapy in patients with carcinoid liver metastases. Acta Oncol. 2008;47:1169-1171.
110. Gulec SA, et al. Safety and efficacy evaluation of Y-90 microsphere treatment using medical internal radiation dosimetry (MIRD) in patients with liver malignancies. J Nucl Med. 2006;47:493P.
111. Murthy R, Mutha P, Lee JH, et al. Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies. J Vasc Interv Radiol. 2008;19(2 Pt 1):299-300.
112. Gulec SA, Pennington K, Hall M, et al. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
113. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682-690.
114. Dhanasekaran R, Khanna V, Lawson D, et al. Survival benefits of Yttrium-90 radioembolization (SIR-Spheres) for hepatic metastasis from melanoma: preliminary study. Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting. J Vasc Interv Radiol. 2009;26(2S):S65, Abs. 167.
115. Gonsalves C, Eschelman DJ, Sullivan KL, et al. Selective internal radiation therapy (SIRT) as salvage therapy for uveal melanoma (UM) hepatic metastases. ASCO Annual Meeting Proceedings. J Clin Oncol. 2009; 27(suppl 7s):Abs. 9066.
116. Yu M, Lewandowski RJ, Wong CO, et al. Yttrium-90 (SIR-Spheres® ) treatment for metastatic cancer to the liver: midterm results. Abstract presented at the Society for Interventional Radiology Conference; March 2006: Abs. 17.
117. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35:222-227.
118. Janssen J, Quinn R, Morris D, et al. Clinical side effects associated with the administration of Y90 SIR-Spheres. 36th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, April 2006: Abs. 53.
119. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101-1106.
120. Wang S, Ho YY, Leung FP, et al. Outcomes following selective internal radiation therapy with SIR-Spheres in non-resectable hepatic malignancy. World Conf Interv Oncol. 2006:Abs. 8145.
121. Wong CY, Savin M, Sherpa KM, et al. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. Cancer Biother Radiopharm. 2006;21:305-313.
122. Cianni R, Satarelli A, Notarianni E, et al. Radioembolism (Yttrium-90) of hepatic liver metastases. A preliminary experience. Cardiovasc Interv Radiol. 2006:Abs. 49.1.9.
123. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008;247:507-515.
124. Sato KT, Omary RA, Takehana C, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20:1564-1569.
125. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resinmicrospheres. Eur Radiol. 2007;17:1320-1330.
126. Lewandowski RJ, Riaz A, Ryu RK, et al. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. J Vasc Interv Radiol. 2009;20:1557-1563.
127. Gulec SA, Mesoloras G, Dezarn WA, et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.
128. Rowe BP, Weiner R, Foster J, et al. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. Conn Med. 2007;71:523-528.
129. Alonso-Burgos A, Iñarrairaegui M, Sangro B, et al. Radioembolisation of liver tumors: determinants of antitumor effect using Y90-labeled resin microspheres. Cardiovascular and Interventional Radiology of Europe (CIRSE) meeting; 2008: Abs. P-74.
130. Ruehl R, Seidensticker M, Denecke T, et al. Selektive interne radioembolisation (SIRT) mit mikrosphären bei extensiven, therapierefraktären, progredienten lebermalignomen, Deutsche Gesellschaft für Nuklearmedizin; 2008: Abs.
131. Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liverdominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol. 2008;19:1427-1433.
132. Johnson DW, Mori KH, O'Laughlin SR, et al. Safety and efficacy of Yttrium-90 labeled microsphere radiation treatment for hepatic metastases. Northeast Florida Med. 2009;60:37-41.
133. Whitney R, Tatum C, Hahl M, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2009;1-5.
134. Seaton T, Naji M, Tait P, et al. Selective internal radiotherapy for unresectable liver tumours: follow up of 74 cases. Presented at the European Association of Nuclear Medicine (EANM) Conference; 2009: Abs. OP374.
135. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33:597-602.
136. Szyszko T, Al-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28: 15-20.